News
- Author:
- Will Pass
Publish date: May 29, 2019
A blueprint for the future of augmented intelligence (AuI) in dermatology – including a definition o...
News
- Author:
- Will Pass
Publish date: May 29, 2019
The alkylator-free regimen of daratumumab plus lenalidomide and dexamethasone appears safe and effective for patients who are ineligible for stem c...
News
- Author:
- Will Pass
Publish date: May 29, 2019
The combination of venetoclax and ibrutinib outperformed previous reports of either of the two agents alone.
News
- Author:
- Will Pass
Publish date: May 20, 2019
Patients treated with local consolidative therapy had a median overall survival of 41.2 months, compared with 17.0 months among patients treated wi...
News
- Author:
- Will Pass
Publish date: May 19, 2019
Two recent studies presented at the American Thoracic Society’s international conference demonstrated the benefits of glucocorticoid therapy among ...
News
- Author:
- Will Pass
Publish date: May 16, 2019
In patients with oropharyngeal cancer, initial staging with PET imaging was associated with better cancer-specific survival than staging with other...
News
- Author:
- Will Pass
Publish date: May 10, 2019
The unusual case shows the importance of molecular cytogenetics and/or immunohistochemistry when making a diagnosis in panniculitis-type lymphomas....
News
- Author:
- Will Pass
Publish date: May 9, 2019
The sensitivity of ctDNA testing for disease recurrence was 100%, compared with 60% for CEA testing, in an observational study of 58 patients with ...
News
- Author:
- Will Pass
Publish date: May 6, 2019
For men with metastatic hormone-sensitive prostate cancer, enzalutamide with ADT offers longer radiographic progression-free survival compared with...
News
- Author:
- Will Pass
Publish date: May 3, 2019
Systemic treatments have altered the disease kinetics for patients with melanoma.
News
- Author:
- Will Pass
Publish date: May 1, 2019
The objective response rate of 85% among 33 heavily pretreated patients suggests “promising efficacy.”
News
- Author:
- Will Pass
Publish date: April 26, 2019
The long-term data confirm that the addition of idelalisib to rituximab significantly improves outcomes for patients with relapsed CLL. However, in...
News
- Author:
- Will Pass
Publish date: April 25, 2019
GENEVA - CTC counts of at least 5 cells per 7.5 mL were associated with reduced overall survival in a retrospective analysis involving 550 patients...
News
- Author:
- Will Pass
Publish date: April 25, 2019
The Brigham and Women’s Hospital tumor classification system was better than the AJCC 8 in predicting metastases and death among 459 patients with ...
News
- Author:
- Will Pass
Publish date: April 25, 2019
GLASGOW – The registry-based study showed that more than 70% of patients who presented with thrombotic thrombocytopenic purpura had neurological ab...
